Table 3.
Comparing Pre- and Posttreatment Clinical and Laboratory Findings
| Study Group |
Placebo Group
|
|||||
|---|---|---|---|---|---|---|
|
Pre-treatment
(Mean±SD) |
Post-treatment
(Mean±SD) |
P value |
Pre-treatment
(Mean±SD) |
Post-treatment
(Mean±SD) |
P value | |
| symptom severity (SNOT-22) | 44.35 ± 14.78 | 23.10 ± 16.85 | <.001 | 43.5 ± 17.46 | 27.55 ± 14.55 | <.001 |
| nasal smear eosinophil, % | 19.5 ± 27.70 | 10.40 ± 19.80 | .01 | 12.50 ± 20.04 | 10.95 ± 25.00 | .405 |
| serum IgE level | 193.50± 160.73 | 183.65± 166.83 | .37 | 187.35± 171.31 | 206.00± 153.85 | .911 |
| interferon-γ level | 0.67 ± 1.23 | 1.42 ± 2.36 | .068 | 0.82 ± 1.50 | 0.27 ± 0.43 | .023 |
| interleukin-4 level | 55.77± 156.55 | 71.29± 239.03 | .84 | 24.54 ± 14.05 | 17.74 ± 16.10 | .089 |
| interleukin-5 level | 1.05 ± 4.69 | 1.90 ± 8.49 | .317 | 1.00 ± 4.47 | 1.45 ± 6.48 | .317 |
Abbreviation: SNOT-22, Sino-Nasal Outcome Test 22. Values presented as mean ± SD.